{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:47:10Z","timestamp":1785833230818,"version":"3.56.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>This paper demonstrates a case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple myeloma (MM) treated with nine different MM therapies. This case report contributes to the already published 16 cases of PML in patients with MM. Additionally, this paper presents an analysis of cases from the United States Food and Drug Administration Adverse Event Report System database (n = 117) with a description of demographics and MM-specific therapies. Patients with MM, that developed PML, were treated with immunomodulatory drugs (97%), alkylating agents (52%), and\/or proteasome inhibitors (49%). Prior to PML diagnosis, 72% of patients received two or more MM therapies. These results indicate that PML in MM is underreported and could be related to treatment with multiple immunosuppressive therapies rather than MM as a disease itself. Physicians should be aware of potential PML in the late stage of heavily treated MM patients.<\/jats:p>","DOI":"10.3389\/fneur.2023.1098930","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T04:14:42Z","timestamp":1683173682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"14","author":[{"given":"Elise","family":"Jonasson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Antulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Tr\u00f8llund Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sejb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood.V95.1.7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Nordic Myeloma Study Group Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide vs. placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance vs. observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nature Reviews Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-020-04294-x","article-title":"Progressive multifocal leukoencephalopathy in multiple myeloma","volume":"100","author":"Koutsavlis","year":"2021","journal-title":"A literature review and lessons to learn Ann Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1752-1947-6-177","article-title":"Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report","volume":"6","author":"Troppmann","year":"2012","journal-title":"J Med Case Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/s1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1098930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T04:14:45Z","timestamp":1683173685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1098930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":15,"alternative-id":["10.3389\/fneur.2023.1098930"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1098930","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"article-number":"1098930"}}